scholarly journals The impact of carbohydrate intake and its sources on hemoglobin A1c levels in Japanese patients with type 2 diabetes not taking anti-diabetic medication

2018 ◽  
Vol Volume 11 ◽  
pp. 53-64
Author(s):  
Hajime Haimoto ◽  
Shiho Watanabe ◽  
Masashi Komeda ◽  
Kenji Wakai
2013 ◽  
Vol 37 ◽  
pp. S227-S228
Author(s):  
Martin Sénéchal ◽  
Neil M. Johanssen ◽  
Damon L. Swift ◽  
Steven N. Blair ◽  
Conrad P. Earnest ◽  
...  

2014 ◽  
Vol 5 (4) ◽  
pp. 229-233
Author(s):  
Yukihiro Bando ◽  
Masayuki Yamada ◽  
Keiko Aoki ◽  
Hideo Kanehara ◽  
Azusa Hisada ◽  
...  

2020 ◽  
Author(s):  
Hirohiko Motoki ◽  
Izuru Masuda ◽  
Shinji Yasuno ◽  
Koji Oba ◽  
Wataru Shoin ◽  
...  

Abstract Background: A sodium glucose cotransporter 2 (SGLT2) inhibitor was recently found to reduce heart failure hospitalization in the EMPA-REG OUTCOMES trial. We have hypothesized that autonomic nerve activity may be modulated by SGLT2 inhibition. The current study aims to investigate the impact of empagliflozin on sympathetic and parasympathetic nerve activity in patients with type 2 diabetes mellitus.Methods: This ongoing study is a prospective, randomized, open-label, multicenter investigation of 134 patients with type 2 diabetes mellitus. The patients are randomly allocated to receive either empagliflozin or sitagliptin with the treatment goal of the Japan Diabetes Society guidelines. Ambulatory electrocardiographic monitoring is performed at the baseline and at 12 and 24 weeks of treatment. Analyses of heart rate variability are performed using the MemCalc method, which is a combination of the maximum entropy method for spectral analysis and the non-linear least squares method for square analysis. The primary endpoint is the change in the low frequency (LF; 0.04-0.15 Hz) / high frequency (HF; 0.15-0.4 Hz) ratio from baseline to 24 weeks.Discussion: This investigation on the effect of EMPagliflozin on cardiac sYmpathetic and parasympathetic neRve activity in JapanEse pAtieNts with type 2 diabetes (EMPYREAN study) offers an important opportunity to understand the impact of SGLT2 inhibition on autonomic nerve activity in patients with type 2 diabetes.Trial Registration: UMIN Clinical Trials Registry identifier UMIN000029194. Registered 19 September 2017, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000033375


BMC Obesity ◽  
2017 ◽  
Vol 4 (1) ◽  
Author(s):  
Ryotaro Bouchi ◽  
Tatsuya Fukuda ◽  
Takato Takeuchi ◽  
Yujiro Nakano ◽  
Masanori Murakami ◽  
...  

Drug Research ◽  
2015 ◽  
Vol 66 (01) ◽  
pp. 18-22 ◽  
Author(s):  
M. Kusunoki ◽  
D. Sato ◽  
T. Nakamura ◽  
Y. Oshida ◽  
H. Tsutsui ◽  
...  

2018 ◽  
Vol 15 (3) ◽  
pp. 187-196
Author(s):  
Adva Eisenberg ◽  
Matthew J Crowley ◽  
Cynthia Coffman ◽  
David Edelman

Objective To assess the impact of a group medical clinic designed for patient with type 2 diabetes mellitus and hypertension on body mass index. Methods Using data from a randomized trial of 239 veterans with type 2 diabetes mellitus, we performed a secondary analysis using analysis of covariance mixed models to explore the effect of a 12-month group medical clinic intervention on change in body mass index vs. usual care. In an exploratory subgroup analysis, we compared change in body mass index between treatment arms stratified by whether patients had >0.5% reduction in hemoglobin A1c at 12 months. Results Baseline body mass index was 33.5 kg/m2. At 12 months, there was no significant difference in change in body mass index between treatment arms (estimate=−0.02, 95% CI −0.51 to 5.05; P = 0.94); body mass index increased by approximately 0.20 points in both groups. There was also no significant difference in change in body mass index between treatment arms by whether or not patients had >0.5% reduction in hemoglobin A1c (estimate=−0.14, 95% CI −1.21 to −0.92; P = 0.79). Discussion Improved glycemic control was not associated with improved body mass index in the group medical clinic intervention. Given their positive effects on other outcomes, group medical clinics for patients with type 2 diabetes mellitus may be more beneficial if focus is shifted towards weight loss.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 787-P
Author(s):  
SATOSHI MATSUNAGA ◽  
HIROHITO SONE ◽  
KINSUKE TSUDA ◽  
YOSHIHARU OSHIDA ◽  
SATOSHI SASAKI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document